In the beginning of October in a 3-day event will take place the 38th GS1 Healthcare Global Conference.
We are proud to announce that SoftGroup is an official sponsor of the GS1 Healthcare Global Conference for the third year in a row. This year the focus is on “the opportunity to explore the power of standardization and the benefits of efficient data exchange”. These exact words said our Operational Director – Iordan Dunkov, announcing our sponsorship of the event.
The event will be possible to attend not only in person but also in a virtual way. It will gather specialists from different sectors of the healthcare industry, discussing updates, experiences, and best practices on pharmaceutical traceability, hospital transformations, and unique device identification (UDI) regulations.
Onsite and online from 3 to 5 October. The program will start from 8:00 am (GMT-3) to 7:30 pm (GMT-3), excluding the last day when the closing session will end at 2:00 pm (GMT-3).
Grand Hyatt São Paulo – São Paulo, Brazil
How to join?
You can register HERE
GS1 is a neutral, global collaboration platform that brings industry leaders, government, regulators, academia, and associations together to develop standards-based solutions to address the challenges of data exchange. GS1 standards are the most widely used system of standards in the world. GS1 empowers industry’s digital transformation by enabling businesses to create a digital version of a product that is as good as the physical one.
SoftGroup is a global software company helping Pharmaceutical and MedTech industries transform their business. The company provides full-stack serialization and aggregation solutions from level 1 to level 5 (from serialization and aggregation machines and software for the production line, through a centralized serialization management system, secure communication among business partners to reporting to National and International Authorities). In the last 20 years of experience, SoftGroup has been recognized as a reliable long-standing traceability partner from Big Pharma Leaders with many production lines to small MAHs with no actual production.